• Fan Y, Murgia M, Linder MI, Mizoguchi Y, Wang C, Łyszkiewicz M, Ziȩtara N, Liu Y, Frenz S, Sciuccati G, Partida-Gaytan A, Alizadeh Z, Rezaei N, Rehling P, Dennerlein S, Mann M, Klein C, “HAX1-dependent control of mitochondrial proteostasis governs neutrophil granulocyte differentiation”, J. Clin Invest., 132(9), e153153 (2022). DOI
   
• Frey L, Ziętara N, Łyszkiewicz M, Marquardt B, Mizoguchi Y, Linder MI, Liu Y, Giesert F, Wurst W, Dahlhoff M, Schneider MR, Wolf E, Somech R, Klein C, “Mammalian VPS45 orchestrates trafficking through the endosomal system”, Blood, 137(14), 1932-1944 (2021). DOI
   
• Mizoguchi Y, Tsumura M, Okada S, Hirata O, Minegishi S, Imai K, Hyakuna N, Muramatsu H, Kojima S, Ozaki Y, Imai T, Takeda S, Okazaki T, Ito T, Yasunaga S, Takihara Y, Bryant VL, Kong XF, Cypowyj S, Boisson-Dupuis S, Puel A, Casanova JL, Morio T, Kobayashi M, “Simple diagnosis of STAT1 gain-of-function alleles in patients with chronic mucocutaneous candidiasis”, J. Leukoc. Biol., 95(4), 667-676 (2014). DOI
   
• Hiramoto T, Ebihara Y, Mizoguchi Y, Nakamura K, Yamaguchi K, Ueno K, Nariai N, Mochizuki S, Yamamoto S, Nagasaki M, Furukawa Y, Tani K, Nakauchi H, Kobayashi M, Tsuji K, “Wnt3a stimulates maturation of impaired neutrophils developed from severe congenital neutropenia patient-derived pluripotent stem cells”, Proc. Natl. Acad. Sci. USA, 110(8), 3023-3028 (2013). DOI
   
• Mizoguchi Y, Fujita N, Taki T, Hayashi Y, Hamamoto K, “Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion”, Am. J. Hematol., 84(5), 295-297 (2009). DOI

To view a more comprehensive list of publications, please click on the "researchmap" link below.

• researchmap
• KAKEN
• ORCID

Born in Hiroshima, Dr. Mizoguchi initially graduated from Hiroshima University in 2003. Thereafter, she worked in a clinical setting and obtained a doctorate from the same university in 2014. In October 2015, she became a Doctoral Research Fellow at Dr. von Hauner’s Children’s Hospital in Germany. She returned to Japan in 2019 and took up a post as a Clinician in the Department of Pediatrics at Hiroshima University Hospital. From January 2021, she took up her current post as Assistant Professor at the Hiroshima University Graduate School of Biomedical and Health Sciences. Dr. Mizoguchi is currently devoting all her efforts into research on gene therapy for rare diseases.

Dr. Mizoguchi, who works at the university hospital as a physician-scientist, is conducting research on the theme of developing gene therapy for congenital neutropenia. Congenital neutropenia is a rare hereditary disease which is characterized by repeated bacterial infections occurring within patients since childhood. Patients with congenital neutropenia are forced to be hospitalized frequently due to recurrent infections. In addition, some patients develop malignant diseases such as leukemia. At the moment, the only curable treatment is bone marrow transplantation, however, transplantations are often accompanied by complications. Therefore, Dr. Mizoguchi is searching for the best way to apply gene editing technology using CRISPR-Cas9 as a gene therapy for patients with congenital neutropenia in clinical practice. Furthermore, through the development of gene therapy for this disease, she believes that she can shed light on rare diseases that tend to be left behind.